Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance

Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance

Purpose: In recent years, immune checkpoint inhibitors have become a major therapeutic method for the treatment of metastatic colorectal cancer (mCRC). Growing evidence indicates that tumour-infiltrating lymphocytes (TILs) in the tumour microenvironment are a prerequisite for the effectiveness of PD...

Full description

Bibliographic Details
Main Authors:	Haisong Xin, Chaoxi Zhou, Guanglin Wang, Yan Liu, Juan Zhang, Youqiang Liu, Baokun Li, Jianfeng Zhang, Mingming Su, Zhihan Li, Guiying Wang
Format:	Article
Language:	English
Published:	Elsevier 2023-02-01
Series:	Heliyon
Subjects:	Metastatic colorectal cancer (mCRC) Programmed death-ligand 1 (PD-L1) CD8 tumour infiltrating lymphocytes (TILs) Heterogeneity Prognosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844023002554

Similar Items

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program Results of a Survey on Daily Practice Patterns for Patients with Metastatic Colorectal Cancer—A Swiss Perspective in the Context of an International Viewpoint
by: Alexander R. Siebenhüner, et al.
Published: (2022-08-01)

Clinical impact of heterogeneously distributed tumor-infiltrating lymphocytes on the prognosis of colorectal cancer
by: Lu Liu, et al.
Published: (2024-01-01)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC
by: Gerald Prager, et al.
Published: (2021-06-01)

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
by: Xiaojing Xu, et al.
Published: (2020-10-01)

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
by: Qizheng Li, et al.
Published: (2022-11-01)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Leukocyte-specific protein 1 is associated with the stage and tumor immune infiltration of cervical cancer
by: Dianqin Xu, et al.
Published: (2025-03-01)

Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital
by: Meiqin Yuan, et al.
Published: (2021-05-01)

Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer
by: Ting Wang, et al.
Published: (2023-03-01)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
by: J. Han van Krieken, et al.
Published: (2017-11-01)

Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?
by: Biaoru Li
Published: (2022-10-01)

Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib
by: Andrea Abbona, et al.
Published: (2023-02-01)

Combined quality and dose-volume histograms for assessing the predictive value of 99mTc-MAA SPECT/CT simulation for personalizing radioembolization treatment in liver metastatic colorectal cancer
by: Hugo Levillain, et al.
Published: (2020-12-01)

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
by: Xia-Hong You, et al.
Published: (2019-08-01)

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China
by: Miaomiao Gou, et al.
Published: (2022-07-01)

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
by: Yuankai Shi, et al.
Published: (2019-05-01)

Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC
by: Edward Zheng, et al.
Published: (2024-06-01)

Case report: Durable response from tegafur/gimeracil/oteracil (S-1) combined with fruquintinib and sintilimab as a third-line treatment for MSS metastatic colorectal cancer with a BRAF V600E mutation
by: Chunxia He, et al.
Published: (2024-12-01)

Predictive and Prognostic Role of Systemic Immune-Inflammation Index (SII) in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
by: Mateusz Malik, et al.
Published: (2024-09-01)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
by: Stefania Napolitano, et al.
Published: (2022-06-01)

Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma
by: Chao Wang, et al.
Published: (2020-12-01)

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
by: Joseph Tintelnot, et al.
Published: (2022-12-01)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
by: Daisuke Kotani, et al.
Published: (2019-12-01)

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
by: Riccardo Giampieri, et al.
Published: (2021-09-01)

Case Report: Chemoimmunotherapy in microsatellite-instability-high advanced goblet cell carcinoma of the colon
by: Arda Ulaş Mutlu, et al.
Published: (2023-07-01)

Racial disparities in metastatic colorectal cancer outcomes revealed by tumor microbiome and transcriptome analysis with bevacizumab treatment
by: Lei Feng, et al.
Published: (2024-01-01)

Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices
by: L. V. Bolotina, et al.
Published: (2018-11-01)

Efficacy and safety of fruquintinib dose‐escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single‐arm, multicenter, phase II study
by: Sirui Tan, et al.
Published: (2023-12-01)

The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD‐L1 expression and tumor‐infiltrating lymphocytes
by: Lu Chen, et al.
Published: (2019-12-01)

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
by: Thomas Morgan Hulen, et al.
Published: (2023-06-01)

Primary tumor location and survival among metastatic colorectal cancer patients treated with systemic chemotherapy and biologic therapies: Retrospective analysis
by: Majed Ramadan, et al.
Published: (2022-01-01)

Tumor Infiltrating Lymphocytes Target HLA-I Phosphopeptides Derived From Cancer Signaling in Colorectal Cancer
by: Sarah A. Penny, et al.
Published: (2021-08-01)

Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
by: Thomas Morgan Hulen, et al.
Published: (2024-07-01)

Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability
by: Tao Wu, et al.
Published: (2023-04-01)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
by: Lucia Scarabel, et al.
Published: (2022-11-01)

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
by: Wafik S. El-Deiry, et al.
Published: (2019-03-01)

Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
by: Mohammad Hossein Kazemi, et al.
Published: (2022-10-01)

Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances
by: Xiang Wang, et al.
Published: (2024-02-01)

Commentary: Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma
by: Zhongling Sun, et al.
Published: (2024-04-01)

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study
by: Sabin Goktas Aydin, et al.
Published: (2023-11-01)